Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune-Boosting cocktail aims to free HIV patients from daily medication

NCT ID NCT04340596

Ongoing ⭐️ CURE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This early-stage trial tests whether an experimental immune-boosting drug called N-803, given alone or with two powerful antibodies, can help people with HIV control the virus after they stop their regular antiretroviral therapy. The study enrolls adults with well-controlled HIV who have been on stable treatment for at least two years. Participants receive the study drugs and then pause their usual HIV medications under close monitoring to see if the virus stays suppressed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an IL-15 superagonist (N-803) with or without broadly neutralizing antibodies (VRC07-523LS and 10-1074)
What this could lead to
If successful, this approach could point toward a functional cure for HIV, allowing people to stop daily antiretroviral therapy without the virus rebounding.
What could go wrong
This is an early phase 1 trial focused on safety, so the chance of achieving sustained HIV control is uncertain. The immune-boosting drug may cause significant side effects, and the virus might still rebound after treatment interruption.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTION

Contacts and locations

Locations

  • Alabama CRS (Site ID# 31788)

    Birmingham, Alabama, 35222, United States

  • Case Clinical Research Site

    Cleveland, Ohio, 44106, United States

  • Chapel Hill CRS (Site ID: 3201)

    Chapel Hill, North Carolina, 27599, United States

  • Columbia P&S CRS

    New York, New York, 10032, United States

  • Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101)

    Boston, Massachusetts, 02114, United States

  • New Jersey Medical School Clinical Research Center CRS [Site ID: 31786]

    Newark, New Jersey, 07103, United States

  • Northwestern University CRS

    Chicago, Illinois, 60611, United States

  • Penn Therapeutics, CRS (Site ID: 6201)

    Philadelphia, Pennsylvania, 19104, United States

  • UCLA CARE Center CRS

    Los Angeles, California, 90035, United States

  • UCSD Antiviral Research Center CRS (Site ID: 701)

    San Diego, California, 92103, United States

  • University of California, San Fransisco HIV/AIDS CRS

    San Francisco, California, 94110, United States

  • Washington University Therapeutics (WT) CRS

    St Louis, Missouri, 63110-1010, United States

  • Weill Cornell Uptown CRS (Site ID: 7803)

    New York, New York, 10065, United States

  • Whitman-Walker Institute, Inc. CRS (Site ID: 31791)

    Washington D.C., District of Columbia, 20005, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.